Recurrent Primary Central Nervous System Neoplasm

14 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Recurrent Primary Central Nervous System Neoplasm

Record	Firm	Date
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548)	National Cancer Institute (NCI)	2021-05-11
Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (NCT03598244)	National Cancer Institute (NCI)	2018-11-27
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (NCT03210714)	National Cancer Institute (NCI)	2018-06-05
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652)	National Cancer Institute (NCI)	2018-04-17
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT03323034)	Children's Oncology Group	2018-01-11
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)	National Cancer Institute (NCI)	2017-11-28
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665)	National Cancer Institute (NCI)	2017-11-13
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02975882)	Children's Oncology Group	2017-08-15
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)	National Cancer Institute (NCI)	2017-07-31
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02808650)	Children's Oncology Group	2017-02-27
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT02780804)	National Cancer Institute (NCI)	2017-01-06
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (NCT02415153)	National Cancer Institute (NCI)	2015-07-14
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors (NCT01709435)	National Cancer Institute (NCI)	2012-11-14

Track Recurrent Primary Central Nervous System Neoplasm automatically

Every clearance here is in the API, with alerts when new ones post.